Physician profile

Brian Patrick Sullivan

Otolaryngology · Mobile, AL

NPI 1932499076

$481.23

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$51.84

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Inspire Medical Systems, INC. $203.81 2021
Cardiva Medical, INC. $119.15 2020-2022
Stryker Corporation $47.33 2020-2024 Audion Et Dilation System
Medtronic USA, INC. $26.51 2020
Intersect Ent, INC. $20.14 2019
Inari Medical, INC. $20.06 2022
Hikma Pharmaceuticals USA $16.34 2024 Ryaltris
Arbor Pharmaceuticals, INC. $16.05 2019
Optinose US, INC. $11.84 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Brian Patrick Sullivan

$481.23

in general payments reported 2019-2025

Years
2019-2024
Top company
Inspire Medical Systems, INC.

https://glasscript.com/doctor/1388150/brian-patrick-sullivan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.